Osteomyelitis - Pipeline Insight, 2024

This “Osteomyelitis- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Osteomyelitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteomyelitis: Understanding

Osteomyelitis: Overview

Osteomyelitis is a serious infection of the bone that can be either acute or chronic. It is an inflammatory process involving the bone and its structures caused by pyogenic organisms that spread through the bloodstream, fractures, or surgery. Healthy intact bone is resistant to infection. The bone becomes susceptible to disease with the introduction of a large inoculum of bacteria, from trauma, ischemia, or the presence of foreign bodies because bone sites to which microorganisms can bind are exposed. Bone can get infected via the hematogenous route of infection through bacteremic seeding of bone from a distant source of infection, contiguous spread from surrounding tissue and joints, or direct inoculation of bone from trauma or surgery. Hematogenous osteomyelitis occurs more frequently in children compared to adults, and long bones are usually affected. In adults, hematogenous osteomyelitis affects the vertebrae most commonly. Contiguous osteomyelitis in young adults usually occurs in the setting of trauma and related surgery, while in older adults, infection is typically related to decubitus ulcers and infected joint arthroplasties. Osteomyelitis associated with vascular insufficiency frequently occurs in the presence of underlying diabetes mellitus. In patients with diabetes, osteomyelitis usually results from compromised blood supply to the lower extremities, which contributes to impaired local immunity and skin healing, promoting the spread of infection. Hematogenous osteomyelitis is primarily monomicrobial, while osteomyelitis due to contiguous spread or direct inoculation is usually polymicrobial or monomicrobial. The most common pathogens in osteomyelitis depend on the patient's age. Effective treatment of osteomyelitis involves a collaborative effort among various medical and surgical specialties. The two main aspects of therapy are surgical containment of the infection and prolonged antibiotics. Prolonged antibiotic therapy is the cornerstone of treatment for osteomyelitis. Laboratory data can be useful in the assessment of osteomyelitis but are usually nonspecific for osteomyelitis. There may or may not be leukocytosis, the elevation of ESR, and C-reactive protein (CRP). The CRP level correlates with clinical response to therapy and may be used to monitor treatment. Blood cultures may be positive, especially in hematogenous osteomyelitis involving the vertebrae, clavicle, or pubis. Radiographic imaging is an essential component of the evaluation of a patient with suspected osteomyelitis. Bone biopsy (either open or percutaneously) is essential to establish the histopathological diagnosis in osteomyelitis, identify the causative pathogen, and provide susceptibility data that helps direct antibiotic therapy.

Osteomyelitis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteomyelitis pipeline landscape is provided which includes the disease overview and Osteomyelitis treatment guidelines. The assessment part of the report embraces, in depth Osteomyelitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteomyelitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteomyelitis R&D. The therapies under development are focused on novel approaches to treat/improve Osteomyelitis.

Osteomyelitis Emerging Drugs Chapters

This segment of the Osteomyelitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteomyelitis Emerging Drugs

Lefamulin: Nabriva Therapeutics LEFAMULIN is a systemic pleuromutilin antibacterial. It inhibits bacterial protein synthesis through interactions (hydrogen bonds, hydrophobic interactions, and Van der Waals forces) with the A- and P-sites of the peptidyl transferase center (PTC) in domain V of the 23s r RNA of the 50S subunit. The binding pocket of the bacterial ribosome closes around the mutilin core for an induced fit that prevents correct positioning oftRNA.

CF 296 : Contra FectContraFect developed a novel, engineered variant of exebacase, CF-296, with potential as a targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections such as prosthetic joint infections andOsteomyelitis.

Bacteriophage therapeutics : Adaptive Phage Therapeutics Local phage administration into the joints, with hardware removal, systemic antibiotics, and antibiotic spacers, successfully managed MDR P. aeruginosa infection of prosthetic joint (PJ) and osteomyelitis. Currently, the phage therapy is in a Phase IIa Randomized, Parallel Group, Double-blind, Repeat Dose, Investigating the Safety, Tolerability, and Efficacy of Phage Treatment and Standard of Care Antimicrobials for Patients with Diabetic Foot Osteomyelitis.

Osteomyelitis: Therapeutic Assessment

This segment of the report provides insights about the different Osteomyelitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteomyelitis

There are approx. 5+ key companies which are developing the therapies for Osteomyelitis. The companies which have their Osteomyelitis drug candidates in the most advanced stage, i.e. phase II include, Adaptive Phage Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Osteomyelitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteomyelitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteomyelitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteomyelitis drugs.

Osteomyelitis Report Insights

• Osteomyelitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteomyelitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteomyelitis drugs?
• How many Osteomyelitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteomyelitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteomyelitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteomyelitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nabriva Therapeutics
• ContraFect
• Adaptive Phage Therapeutics
• Durata Therapeutics

Key Products

• Bacteriophage therapeutics
• CF-296
• Lefamulin
• Dalbavancin